XML 38 R27.htm IDEA: XBRL DOCUMENT v3.20.2
Long-Term Investments (Tables)
 3 Months Ended
Mar. 31, 2020
Schedule of ownership percentages of investee
   Ownership percentage    
   March 31,   December 31,   Accounting
Name of related party  2020   2019   treatments
Braingenesis Biotechnology Co., Ltd.   0.17%   0.17%  Cost Method
Genepharm Biotech Corporation   0.72%   0.72%  Cost Method
BioHopeKing Corporation   7.13%   7.13%  Cost Method
BioFirst Corporation   15.89%   15.89%  Equity Method
Rgene Corporation   31.61%   31.61%  Equity Method
Schedule of extent the investee relies

Name of related party  The extent the investee relies on the Company for its business  
Braingenesis Biotechnology Co., Ltd.  No specific business relationship
Genepharm Biotech Corporation  No specific business relationship
BioHopeKing Corporation  Collaborating with the Company to develop and commercialize drugs
BioFirst Corporation  Loaned from the investee and provides research and development support service
Rgene Corporation  Collaborating with the Company to develop and commercialize drugs
Schedule of long-term investment

   March 31,
2020		   December 31,
2019		 
Non-marketable Cost Method Investments, net  (Unaudited)     
Braingenesis Biotechnology Co., Ltd.  $7,301   $7,367 
Genepharm Biotech Corporation   22,291    22,493 
BioHopeKing Corporation   1,980,361    1,998,310 
Sub total   2,009,953    2,028,170 
Equity Method Investments, net          
BioFirst Corporation   1,254,247    1,336,449 
Rgene Corporation   -    - 
Total  $3,264,200   $3,364,619 
Schedule of equity investments

   Three Months Ended
March 31,		 
   2020   2019 
   (Unaudited) 
Share of equity method investee losses  $(70,411)  $(66,205)
BioFirst [Member]  
Schedule of balance sheets

   March 31,
 2020		  

December 31,
2019

 
   (Unaudited)     
Current Assets  $1,235,043   $1,350,701 
Noncurrent Assets   7,238,415    7,450,032 
Current Liabilities   2,105,938    2,060,460 
Noncurrent Liabilities   65,847    78,888 
Shareholders' Equity   6,301,673    6,661,385 
Schedule of statements of operation

   Three Months Ended
March 31,		 
   2020   2019 
   (Unaudited) 
Net sales  $12,110   $10,334 
Gross profit   1,578    1,882 
Net loss   (325,652)   (307,034)
Share of losses from investments accounted for using the equity method   (70,411)   (66,205)
Rgene [Member]  
Schedule of balance sheets
   March 31,
2020		   December 31,
2019		 
   (Unaudited)     
Current Assets  $136.936   $82,254 
Noncurrent Assets   161,255    62,768 
Current Liabilities   462,667    312,950 
Noncurrent Liabilities   62,801    - 
Shareholders' Deficit   (227,277)   (167,928)
Schedule of statements of operation
   Three Months Ended
March 31,		 
   2020   2019 
   (Unaudited) 
Net sales  $      $   
Gross Profit          
Net loss   (21,889)   (22,662)
Share  of loss from investments accounted for using the equity method   -    -